Compare IDEXX Laboratories, Inc. (IDXX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $572.25 (market cap $46.22B), while Virgin Galactic Holdings, Inc. trades at $3.3 (market cap $498.02M). The key difference: IDEXX Laboratories, Inc. is far larger — about 92.8× Virgin Galactic Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| IDXX | SPCE | |
|---|---|---|
Market Cap | $46.22B | $498.02M |
Sector | Health | Industrials |
52-Week High | $766.68 | $7.52 |
52-Week Low | $526.44 | $2.17 |
Enterprise Value | $47.12B | $597.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Virgin Galactic (SPCE) trades at $3.26, up 0.77% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company continues to face significant fundamental challenges with negative profit margins (-19,781.3% net income margin) and declining revenue, though recent earnings have consistently beaten expectations. Cash flow remains negative but shows improvement trend from -$207M in 2022 to -$35M in 2025.
While technical momentum appears positive, SPCE's fundamental weakness and high cash burn present substantial risks. The stock offers speculative appeal for investors betting on space tourism commercialization, but requires careful risk management given persistent losses and competitive pressures in the emerging space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
